Catalysts for Qilu Pharmaceutical Co Ltd
4 tracked
Apr 30, 2026
phase 2 completion
Qilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)
iruplinalkib
→
Apr 30, 2026
phase 1 initiation
Qilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)
QLS-5212
→
Feb 17, 2026
approval
MEROPENEM — FDA approval
MEROPENEM
→
Jul 22, 2024
approval
MEROPENEM — FDA approval
MEROPENEM
→